# reload+after+2024-01-21 17:45:45.769667
address1§740 McCurdy Road
address2§Suite 100
city§Kelowna
state§BC
zip§V1X 2P7
country§Canada
phone§250-765-6424
website§https://lexariabioscience.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
fullTimeEmployees§5
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Christopher A. Bunka', 'age': 61, 'title': 'Chairman & CEO', 'yearBorn': 1962, 'fiscalYear': 2023, 'totalPay': 291193, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John M. Docherty M.Sc.', 'age': 54, 'title': 'President & Director', 'yearBorn': 1969, 'fiscalYear': 2023, 'totalPay': 290465, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mike  Shankman', 'title': 'Chief Financial Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Kristin  Hamilton', 'title': 'Director of Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Vanessa  Carle', 'title': 'Head of Legal', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Philip N. Ainslie Ph.D.', 'title': 'Advisor & Consultant', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.822
priceToSalesTrailing12Months§61.330326
currency§USD
dateShortInterest§1702598400
forwardEps§-0.51
exchange§NCM
quoteType§EQUITY
shortName§Lexaria Bioscience Corp.
longName§Lexaria Bioscience Corp.
firstTradeDateEpochUtc§1610461800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fa0cac90-d3bd-318b-a822-2ddacc7019ba
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§2.0
targetMeanPrice§6.0
targetMedianPrice§6.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§6.174
grossMargins§0.86074996
ebitdaMargins§0.0
trailingPegRatio§None
